RECURRENT MALIGNANT GLIOMA

This study is testing if the drug pembrolizumab can help control or shrink recurrent malignant brain tumors (gliomas) that have a specific high-mutation genetic pattern. The drug works by activating the body's own immune system to fight the cancer cells. The study is for adults w…

This study is testing how well a drug called selpercatinib works for children and young adults with advanced or hard-to-treat cancers that have a specific genetic change in the RET gene. The drug is designed to block the growth of cancer cells with this change. Participants take …

This early-stage study is testing a new two-part treatment for aggressive brain tumors that have returned after standard therapy. Doctors place genetically modified neural stem cells into the brain to make the tumor more sensitive to a chemotherapy drug called irinotecan. The mai…

This study is testing a drug called tipifarnib in children and young adults whose advanced cancers have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug as a pill or through a fee…

This study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…

This early-phase trial is testing a new type of personalized immunotherapy for patients with malignant brain tumors (gliomas) that have returned or stopped responding to standard treatments. Doctors collect a patient's own immune cells (T-cells), genetically modify them in a lab …

This is an early-stage safety study for a new type of CAR T-cell therapy designed for adults with a specific type of recurrent brain cancer called glioblastoma. The main goals are to find the safest dose and understand the side effects. Doctors will collect a patient's own immune…

This study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…

This study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…

This study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …

This study is testing a new type of MRI scan designed to see brain tumors in more detail. It aims to help doctors better detect, understand, and potentially track how tumors respond to treatment. The study involves patients with glioma brain tumors who are scheduled for surgery o…

This study aims to understand which treatment sequences work best for patients whose aggressive brain tumors have returned. Researchers will analyze the medical records of about 1,000 patients to see how different chemotherapy and targeted drug combinations affect survival and ti…